Northern Trust Corp Oramed Pharmaceuticals Inc. Transaction History

Northern Trust Corp

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$1.93 - $13.1 $507 - $3,445	-263 Reduced 2.22%	11,569 $25,000
Q4 2022 Feb 13, 2023	SELL	$5.88 - $12.03 $12,306 - $25,178	-2,093 Reduced 15.03%	11,832 $142,000
Q3 2022 Nov 14, 2022	BUY	$4.6 - $9.91 $1,311 - $2,824	285 Added 2.09%	13,925 $90,000
Q2 2022 Aug 12, 2022	SELL	$3.72 - $9.0 $999,705 - $2.42 Million	-268,738 Reduced 95.17%	13,640 $62,000
Q1 2022 May 13, 2022	BUY	$8.19 - $13.89 $321,482 - $545,224	39,253 Added 16.15%	282,378 $2.44 Million
Q4 2021 Feb 08, 2022	BUY	$12.98 - $29.75 $224,476 - $514,496	17,294 Added 7.66%	243,125 $3.47 Million
Q3 2021 Nov 15, 2021	BUY	$12.13 - $23.82 $178,905 - $351,321	14,749 Added 6.99%	225,831 $4.96 Million
Q2 2021 Aug 13, 2021	BUY	$8.34 - $14.59 $1.76 Million - $3.08 Million	211,082 New	211,082 $2.82 Million
Q1 2019 May 13, 2019	SELL	$2.95 - $3.64 $53,893 - $66,499	-18,269 Closed	0 $0
Q4 2018 Feb 12, 2019	BUY	$3.0 - $4.94 $777 - $1,279	259 Added 1.44%	18,269 $55,000
Q3 2018 Nov 14, 2018	BUY	$4.64 - $7.11 $83,566 - $128,051	18,010 New	18,010 $88,000

7.4M

2.1K

Ticker ORMP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,827,100
Market Cap $92.4M
Description
Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for th...

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

Stay updated on Northern Trust Corp with notifications on news.